Ginsenosides are a class of saponins predominantly found in Panax ginseng and other ginseng species [1]. These compounds possess a complex structure comprising a steroid-like aglycone (the non-sugar portion) linked to one or more sugar moieties (glycosides) [2]. The aglycone component is a triterpenoid, and the sugar molecules are typically glucose, rhamnose, or other sugars with the aglycone backbone connected via a glycosidic bond [3]. Sugars enhance the solubility, bioavailability, and pharmacological activity of ginsenoside [4]. Consequently, the structure of ginsenosides is pivotal for their biological and pharmacological effects. Generally, ginsenosides are categorized into two primary groups based on the position and type of sugar attached to the aglycone: protopanaxadiol-type (PPD) and protopanaxatriol-type (PPT) [5]. PPD-type ginsenosides feature a hydroxyl group at the 6-position of the aglycone, whereas PPT-type ginsenosides have a hydroxyl group at the 20-position [6]. The presence of different sugars and functional groups at specific positions further defines the specific type of ginsenoside (such as Rg1, Rg3, Re, Rh1, etc.) [7].

Among these, ginsenoside Rg3 is a notable active compound found in Panax ginseng and has been recognized for its various therapeutic properties [8]. Ginsenoside Rg3 exists in two isomeric forms, 20(S)-Rg3 and 20(R)-Rg3, which differ in the stereochemistry of their hydroxyl groups at the 20th carbon position (Fig. 1) [9]. These two isomers exhibit distinct biological activities, with 20(S)-Rg3 often demonstrating greater biological activity than 20(R)-Rg3 [9,10]. The fundamental skeleton is typically of the dammarane type, which constitutes the core structure of most ginsenosides, including Rg3 [11]. This backbone comprises carbon atoms arranged in a specific configuration, which can be modified by functional groups such as hydroxyl (-OH), carbonyl, and acetoxy groups [12].

Ginsenoside Rg3 is recognized for its extensive pharmacological activities, including anticancer, anti-inflammatory, neuroprotective, and cardiovascular effects [9]. Nevertheless, its pharmacokinetic properties pose significant challenges, particularly owing to its low bioavailability. Upon oral administration, Rg3 is absorbed in the gastrointestinal tract; however, its large molecular structure and glycosidic linkage (with sugar groups) result in poor absorption [13]. The compound undergoes extensive first-pass metabolism in the liver, where it is transformed into various metabolites, some of which may retain their pharmacological effects [14]. The absorption process is further impeded by the conversion of Rg3 to its aglycone form by intestinal microbes [15]. Although this conversion can enhance the absorption, it occurs relatively slowly. Additionally, Rg3 is rapidly eliminated from the body, primarily through urine, contributing to its short half-life and limiting its therapeutic efficacy [16].

To enhance its bioavailability, researchers are investigating various strategies, such as nanoencapsulation, lipid-based formulations, and prodrug designs [17–21]. These approaches aim to improve the solubility, stability, and controlled release of Rg3 into the body, thereby increasing its therapeutic effectiveness [22]. Biologically, Rg3 demonstrates potent anticancer activity by promoting apoptosis in various cancer cells and inhibiting tumor growth [23]. It can suppress angiogenesis, the process of new blood vessel formation required by tumors for growth, and also reduce cancer cell migration and invasion, thereby preventing metastasis [24]. Rg3 is also known for its anti-inflammatory effects, as it suppresses the production of pro-inflammatory cytokines such as interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) and modulates pathways such as nuclear factor kabba B (NF-κB), which play a central role in inflammatory responses [25]. Furthermore, Rg3 scavenges reactive oxygen species (ROS), thereby reducing oxidative stress and protecting cells from damage [26]. This antioxidant activity contributes to its neuroprotective, cardioprotective, and anti-aging effects.

Ginsenoside Rg3 exhibits neuroprotective properties, including enhancement of cognitive function and memory, which may be beneficial in the management of neurodegenerative conditions such as Alzheimer’s and Parkinson’s diseases [27,28]. It facilitates neurogenesis and mitigates neuroinflammation, thereby protecting the brain against neurodegenerative damage [29]. In the context of cardiovascular health, Rg3 contributes to the reduction of blood pressure, improvement of blood circulation, and prevention of myocardial injury resulting from ischemia or heart attack [30]. Furthermore, Rg3 has been shown to modulate the immune system by enhancing the activity of immune cells and improving the body’s response to infections or cancer therapies [31]. Some studies indicate that Rg3 may enhance insulin sensitivity and regulate blood glucose levels, which could be advantageous for the management of diabetes [32]. Additionally, Rg3 may assist in hormone regulation, particularly in menopausal women, by alleviating symptoms, such as hot flashes [33]. Despite its significant therapeutic potential, the low bioavailability of Rg3 necessitates careful formulation to augment its clinical efficacy.

This review provides a comprehensive analysis of the anticancer and skincare applications of Ginsenoside Rg3, emphasizing its ability to modulate key cellular and molecular pathways. By focusing on mechanisms such as oxidative stress, apoptosis, inflammation, angiogenesis, and cellular metabolism, we highlight Rg3’s potential as a multifaceted therapeutic agent in both oncology and dermatology (Fig. 2). Moreover, we explore its synergistic effects when combined with conventional treatments, positioning Rg3 as a promising integrative approach that bridges natural compounds and modern therapies. Finally, we identify current research gaps and propose future directions to enhance the clinical translation of Rg3-based interventions.

Ginsenoside Rg3, a potent bioactive compound derived from ginseng, confers numerous skin care benefits owing to its anti-aging, anti-inflammatory, and regenerative properties [34]. It functions as a powerful antioxidant that mitigates oxidative stress and prevents premature signs of aging, such as wrinkles and loss of elasticity [35]. Additionally, Rg3 inhibits inflammation, rendering it effective for treating conditions such as acne and eczema. It also promotes collagen synthesis, thereby enhancing skin firmness and elasticity, while supporting skin regeneration and wound healing [36]. Its photoprotective effects help shield the skin from UV damage and may also regulate pigmentation, contributing to skin brightening and addressing hyperpigmentation.

Ginsenoside Rg3 plays a significant role in mitigating skin aging through its multifaceted effects on collagen metabolism and oxidative stress [37]. It contributes to the maintenance of the skin structure by inhibiting the activity of matrix metalloproteinases (MMPs), enzymes responsible for the degradation of collagen and elastin in the skin [38]. MMPs are often upregulated by UV radiation and environmental stressors, leading to skin aging (Fig. 3). By inhibiting these enzymes, Rg3 helps to preserve the integrity of the extracellular matrix of the skin, thereby preventing the breakdown of essential structural proteins. For instance, when the stereoisomers of both 20(S)-ginsenoside Rg3 and 20(R)-ginsenoside Rg3 were co-cultured with HaCaT cells (human immortalized keratinocytes) and human dermal fibroblast cells prior to UV-B irradiation at 70 mJ/cm², a greater reduction in UV-B-induced ROS levels was observed for 20(S)-ginsenoside Rg3 [39]. In addition, 20(S)-ginsenoside Rg3 suppressed MMP-2 activity in HaCaT cells. These findings suggest that ginsenoside Rg3 has stereoselective anti-photoaging properties.

Additionally, Rg3 stimulates collagen production, a crucial component for maintaining skin elasticity and firmness [40]. Collagen production declines naturally with age, contributing to the development of wrinkles and loss of skin elasticity [41]. By enhancing collagen synthesis, Rg3 helps counteract these aging signs, promote a youthful appearance, and improve skin texture. Treatment of UV-exposed human dermal fibroblasts with Rg3 results in an increase in extracellular matrix (ECM) proteins, including collagen and elastin, while reducing the activity of inhibitory collagenases such as MMP-2 and MMP-3 [42]. Furthermore, Rg3 enhanced the expression of antioxidant proteins, such as heme oxygenase-1 (HO-1) and nuclear factor erythroid 2-related factor 2 (Nrf2) [43].

One of Rg3’s most potent attributes is its antioxidant activity [44]. Rg3 neutralizes free radicals, which are unstable molecules that induce oxidative stress, and accelerates skin aging by damaging cellular components, proteins, and DNA. Ding et al. prepared Rg3-loaded gel and examined the change in oxidative stress of HaCaT cells exposed to UVB irradiation [45]. Rg3 formulation effectively mitigated UVB-induced oxidative stress, pro-inflammatory responses, and apoptotic activity. Moreover, Rg3-Gel reduced the generation of intracellular ROS and malondialdehyde (MDA) while improving the expression of antioxidant enzymes such as glutathione peroxidase (GSH-Px) and superoxide dismutase (SOD) [45]. Additionally, elevated levels of pro-inflammatory cytokines, such as interleukin-1β (IL-1β), TNF-α, inducible nitric oxide synthase (iNOS), and cyclooxygenase-2 (COX-2), caused by UVB irradiation were significantly suppressed by Rg3-Gel treatment.

This antioxidant effect reduces oxidative damage to skin cells, helping to slow down the appearance of fine lines, wrinkles, and age spots. Collectively, these effects render Rg3 a valuable compound in anti-aging skincare, working synergistically to both prevent and repair the visible signs of aging by protecting and enhancing the skin collagen network and reducing oxidative stress.

Ginsenoside Rg3 has demonstrated significant potential in enhancing skin barrier function and protecting the skin from UV-induced damage and environmental stressors [46]. One of the primary mechanisms by which Rg3 offers protection is the reduction in oxidative damage caused by UV exposure [47]. UV radiation generates free radicals and ROS, which can damage skin cells, accelerate aging, and impair barrier function in the skin [48]. The antioxidant properties of Rg3 neutralize these harmful molecules, thereby reducing oxidative stress and preserving the skin integrity.

Ginsenoside Rg3 has been shown to repair UVB-induced skin barrier damage in a BALB/c hairless mouse model (Fig. 4) [49]. Its protective effects were evident in the mitigation of UVB-induced epidermal barrier dysfunction, characterized by increased epidermal thickness, elevated transepidermal water loss, and diminished water content in the stratum corneum, without causing weight changes. Rg3 also inhibited the phosphorylation of JNK, p38, and ERK in UVB-irradiated HaCaT cells. A mixture of ginsenosides exhibited similar protective effects by inhibiting the MAPK pathway and enhancing the upregulation of involucrin and aquaporin 3 expression, comparable to treatment with intact Rg3.

Furthermore, Rg3 strengthens the skin’s natural defense mechanisms by improving skin barrier function. The skin barrier is crucial for maintaining hydration, preventing the penetration of harmful microorganisms, and protecting the skin against environmental pollutants. Rg3 aids in regulating the expression of proteins involved in maintaining the skin barrier, thereby enhancing its capacity to retain moisture and protect against environmental stressors.

Han et al. demonstrated that Rg3 suppresses thymic stromal lymphopoietin (TSLP) production by downregulating the murine double minute 2/hypoxia-inducible factor 1-α (MDM2/HIF1α) signaling pathway in an in vitro model of phorbol 12-myristate 13-acetate plus calcium ionophore A23187 (PMACI)-stimulated human mast cell line (HMC-1 cell line) and a phorbol 12-myristate 13-acetate (PMA)-induced mouse ear edema model of inflammation [50]. This dual action of protecting against oxidative stress and supporting barrier function renders Rg3 particularly beneficial for shielding the skin from both UV damage and other environmental stressors, such as pollution and harsh weather conditions. By strengthening the resilience of the skin to external damage and promoting a healthier barrier, Rg3 can reduce the risk of inflammation, irritation, and photoaging, making it a valuable ingredient in products designed for skin protection and repair.

Ginsenoside Rg3 demonstrates substantial anti-inflammatory properties, rendering it advantageous for mitigating skin redness, sensitivity, and inflammation associated with dermatological conditions such as acne, eczema, and other related conditions [51]. Rg3 modulates various inflammatory pathways by inhibiting the activation of proinflammatory mediators and cytokines [52]. The principal mechanism of Rg3 is its ability to suppress the production of inflammatory cytokines, including TNF-α, IL-1β, and IL-6, which are typically elevated during inflammatory responses in the skin [53]. These cytokines are responsible for initiating inflammation, redness, and swelling in conditions, such as acne and psoriasis. By downregulating these cytokines, Rg3 contributes to the reduction in the overall inflammatory response in the skin, leading to decreased irritation and sensitivity.

Furthermore, Rg3 inhibits the activation of NF-κB, a critical transcription factor involved in inflammatory process [54]. By suppressing NF-κB, Rg3 diminishes the expression of various proinflammatory enzymes and proteins, thereby effectively reducing the overall inflammatory response. This action aids in calming irritated skin, reducing redness, and preventing flare-ups, which are commonly observed in inflammatory skin conditions. Through these mechanisms, Rg3 can be efficacious in alleviating the symptoms of inflammatory skin disorders, making it a promising ingredient in formulations aimed at soothing sensitive or acne-prone skin. Its ability to modulate inflammatory pathways without causing irritation is an ideal candidate for products targeting both the symptoms and the underlying causes of skin inflammation. The beneficial effects of Ginsenoside Rg3 on various skin-related applications, including anti-aging, wound healing, and UV protection, are summarized in Table 1.

Ginsenoside Rg3, a bioactive compound derived from Panax ginseng, exhibits significant anticancer properties via various mechanisms. It induces apoptosis in cancer cells by activating proapoptotic proteins and inhibiting antiapoptotic factors. Additionally, Rg3 suppresses tumor angiogenesis by inhibiting vascular endothelial growth factor (VEGF) and associated signaling pathways, while reducing cancer cell migration and invasion by targeting MMPs and epithelial-to-mesenchymal transition (EMT) [55]. Furthermore, it modulates inflammatory pathways, reduces oxidative stress through antioxidant activity, and arrests the cell cycle at critical checkpoints. Ginsenoside Rg3 also enhances the immune system by activating natural killer (NK) cells, which are essential components of the innate immune system responsible for directly attacking tumor cells. Moreover, Rg3 stimulates other immune cells such as T lymphocytes and macrophages to augment their tumor-targeting capabilities, thereby fostering a more coordinated and effective immune response against cancer [56]. These combined actions indicate that Rg3 is a promising candidate for cancer therapy.

Ginsenoside Rg3 has demonstrated potential as a potent inducer of apoptosis in cancer cells through its regulation of key apoptotic signaling molecules, including B-cell lymphoma 2 (Bcl-2) family proteins, caspases, and other critical components involved in programmed cell death [57]. One of the primary mechanisms by which Rg3 induces apoptosis is by modulating the balance between pro-apoptotic and anti-apoptotic proteins in the Bcl-2 family [58]. The Bcl-2 family comprises pro-survival proteins, such as Bcl-2 and Bcl-xL, as well as pro-apoptotic proteins, such as Bax, Bak, and Bid [59]. In healthy cells, pro-survival Bcl-2 proteins prevent apoptosis by inhibiting the activation of proapoptotic proteins. Rg3 disrupts this balance by downregulating the expression of anti-apoptotic Bcl-2 proteins and upregulating pro-apoptotic proteins such as Bax and Bak.

For instance, Rg3 upregulates the expression of Bax and downregulates Bcl-2 in osteosarcoma cells [57]. Increased Bax expression facilitates the formation of Bax-Bcl-2 heterodimers, which activate caspase-9 and subsequently cleave the downstream factor procaspase-3, ultimately promoting apoptosis. Additionally, the phosphoinositide 3-kinase/protein kinase B/mechanistic target of rapamycin (PI3K/AKT/mTOR) signaling pathway, which plays a critical role in oncogene activation, tumor cell proliferation, and inactivation of osteosarcoma-suppressing mechanisms, is involved in this process. This shift promotes mitochondrial membrane permeabilization, an essential stage in the apoptotic process [60]. Once the mitochondria are compromised, cytochrome c is released into the cytoplasm where it activates caspases, a family of protease enzymes essential for executing apoptosis.

Kim et al. demonstrated that MDA-MB-231 breast cancer cells treated with 30 μM Rg3 had an increased proportion of apoptotic cells [58]. Treatment with Rg3 increased the ratio of pro-apoptotic Bax to anti-apoptotic Bcl-2, induced depolarization of mitochondrial membrane potential, and initiated the release of cytochrome c from the mitochondria. Rg3 enhanced the activation of caspase-9, an initiator caspase that initiates the apoptotic cascade, and caspase-3, an effector caspase responsible for the breakdown of cellular components. These caspases cleave various cellular substrates, leading to cell death and the characteristic morphological changes observed in apoptosis, such as cell shrinkage, DNA fragmentation, and membrane blebbing.

In addition to its effects on the Bcl-2 family and caspases, Rg3 may also modulate other apoptotic signaling pathways, including the activation of p53, a tumor suppressor protein that can induce apoptosis in response to DNA damage [61]. By promoting the activation of p53 and other stress-induced signaling molecules, Rg3 further enhances the apoptotic response in tumor cells.

Kim et al. investigated the mechanisms underlying the anti-proliferative and pro-apoptotic effects of Rg3 in MDA-MB-231 breast cancer cells, which exhibit constitutive NF-κB activation and a mutant p53 form (Fig. 5) [62]. Their findings indicated that Rg3 suppressed NF-κB signaling, potentially by inactivating ERK and Akt, and destabilizing mutant p53. These effects likely contributed to the downregulation of Bcl-2 expression, ultimately triggering apoptosis in MDA-MB-231 breast cancer cells. Through these mechanisms, Rg3 induces apoptosis in cancer cells by disrupting the regulatory networks that control cell survival and death, making it a promising candidate for cancer therapy, particularly as an adjuvant treatment to enhance the effects of conventional chemotherapies.

Ginsenoside Rg3 has demonstrated significant anti-metastatic properties, particularly in the inhibition of cancer cell migration and invasion, which are critical stages in the progression of metastasis. These effects are primarily mediated by the regulation of EMT and inhibition of MMPs.

Inhibition of EMT: EMT is a crucial process in cancer metastasis, wherein epithelial cells transition by losing their cell-cell adhesion properties and acquiring mesenchymal traits, enabling them to migrate and invade the surrounding tissues [63]. Rg3 modulates EMT by reversing molecular changes that promote this transition. It reduces the expression of mesenchymal markers, such as N-cadherin, vimentin, and fibronectin, while promoting the expression of epithelial markers, such as E-cadherin. By restoring epithelial characteristics, Rg3 helps prevent the detachment of cancer cells from the primary tumor, thereby inhibiting their ability to spread to distant organs.

Tian et al. confirmed that Rg3 inhibits EMT and invasion in lung cancer through a glycobiological mechanism [64]. In their study, researchers observed that treatment with Ginsenoside Rg3 at 25, 50, and 100 μg/mL effectively suppressed cell migration and invasion. These inhibitory effects were confirmed through wound healing assays, which measure the closure of artificial gaps in cell monolayers, and transwell assays, which assess the ability of cells to migrate through a porous membrane. Furthermore, Rg3 significantly influenced the expression of EMT marker proteins, which is a key process in cancer metastasis. Specifically, it upregulated E-cadherin, a marker of the epithelial phenotype associated with reduced metastatic potential, while downregulating Snail, N-cadherin, and vimentin, all markers linked to the mesenchymal phenotype and enhanced cell motility. Consequently, these molecular changes translated to tangible in vivo benefits, as Rg3 treatment led to a notable reduction in tumor volume and weight in a xenograft mouse model. Additionally, when tumor cells were introduced via tail vein injection to mimic metastatic spread, Rg3 significantly reduced the number of metastatic nodules in lung tissues.

Inhibition of MMPs: MMPs are enzymes that degrade the ECM, a crucial step in the invasion of cancer cells through tissue barriers [65]. Rg3 has been shown to suppress the activity of MMPs, particularly MMP-2 and MMP-9, which are critical for degrading type IV collagen and other ECM components [66]. By inhibiting MMP production and activation, Rg3 reduces the capacity of cancer cells to infiltrate the surrounding tissue and migrate to distant sites, which is a fundamental aspect of metastasis. Through these mechanisms, Rg3 exerts a dual effect on metastatic progression by preventing the acquisition of invasive properties through EMT inhibition and by limiting the physical ability of cancer cells to invade the ECM through MMP inhibition. These anti-metastatic effects make Rg3 a promising candidate for cancer therapy, particularly in combination with other treatments aimed at reducing the spread of cancer and improving patient prognosis.

Wang et al. demonstrated that Rg3 effectively inhibits cell migration and invasion in both HNE1 and CNE2 nasopharyngeal carcinoma cell lines, underscoring its potential as an anti-metastatic agent [67]. Rg3 reduced the levels of MMP-2 and MMP-9 in both HNE1 and CNE2 nasopharyngeal carcinoma cell lines, thereby inhibiting extracellular matrix degradation associated with tumor progression. Moreover, Rg3 significantly modulated the expression of EMT markers, increasing E-cadherin and decreasing Vimentin and N-cadherin levels, indicating reversal of the mesenchymal phenotype. Additionally, Rg3 suppressed the expression of key EMT-related transcription factors, particularly zinc finger E-box-binding homeobox 1 (ZEB1), further reinforcing its role in mitigating cancer cell migration and invasion. These findings suggest that Rg3 regulates MMP-2 and MMP-9 expression and inhibits EMT in nasopharyngeal carcinoma.

Ginsenoside Rg3 has demonstrated potential in inhibiting tumor angiogenesis, the process by which new blood vessels are formed to supply oxygen and nutrients to growing tumors [68]. Tumor angiogenesis is driven by several pro-angiogenic factors, with VEGF being the most critical. Rg3 interferes with this process by suppressing the expression of VEGF and other key angiogenic factors, thereby limiting the ability of tumors to establish blood supply.

Suppression of VEGF Expression: VEGF is a key regulator of angiogenesis and plays a crucial role in promoting endothelial cell proliferation, migration, and formation of new blood vessels [69–71]. Rg3 inhibits the expression of VEGF at both transcriptional and translational levels, reducing the activation of VEGF receptors on endothelial cells, which in turn diminishes their ability to form new blood vessels. By downregulating VEGF, Rg3 starves the tumor, restricting its growth and ability to spread.

For example, Lv et al. demonstrated that Rg3 at concentrations of 0, 25, 50, and 100 μg/mL significantly inhibited cell viability, migration, invasion, angiogenesis, and the protein expression of N-cadherin, Vimentin, COX2, and VEGF in A549 and H1299 lung cancer cells in a dose-dependent manner [72]. Conversely, Rg3 treatment promoted E-cadherin expression, suggesting its potential to suppress EMT and tumor progression. COX2 overexpression significantly reversed the effects of Rg3 on cell viability, migration, invasion, angiogenesis, and expression of EMT-related proteins in lung cancer cells. However, these reversed effects were counteracted by VEGF knockdown, indicating that VEGF plays an essential role in mediating the effect of COX2 on tumor progression. In conclusion, Rg3 reduced migration, invasion, and angiogenesis in lung cancer cells by inhibiting the expression of COX2 and VEGF, highlighting its potential as a therapeutic agent to target both inflammatory and angiogenic pathways in cancer.

Modulation of Angiogenic Signaling Pathways: In addition to VEGF, other angiogenic signaling molecules such as platelet-derived growth factors (PDGFs), fibroblast growth factors (FGFs), and MMPs play a key role in tumor angiogenesis. Rg3 has been shown to modulates several of these factors. For instance, it may reduce the secretion of MMPs, which are involved in the breakdown of the ECM and creation of pathways for endothelial cell migration. By suppressing these angiogenic mediators, Rg3 further inhibits the formation of new blood vessels within tumors.

Inhibition of Angiogenesis through Hypoxia-Inducible Factors (HIFs): Under low-oxygen conditions (hypoxia), tumors often activate hypoxia-inducible factors (HIFs), which subsequently stimulate the expression of VEGF and other angiogenic factors [73–75]. Rg3 has been shown to reduce the activity of HIFs, thereby preventing the upregulation of VEGF and other proangiogenic molecules under hypoxic conditions [76]. This additional layer of regulation further enhances Rg3’s ability to limit tumor angiogenesis.

By inhibiting VEGF and other key angiogenic factors, Rg3 effectively disrupts the tumor’s ability to establish and maintain blood supply, rendering it a promising candidate for anti-cancer therapies, particularly in limiting tumor growth and metastasis by targeting angiogenesis. For instance, Zeng et al. demonstrated that Rg3 suppresses the synthesis of HIF-1α and VEGF proteins in bone marrow stem cells derived from patients with acute leukemia [77]. Rg3 treatment resulted in a reduction in serum levels of HIF-1α and VEGF in patients, indicating its potential to inhibit key factors involved in tumor progression and angiogenesis. Mechanistically, Rg3 downregulated the phosphorylation of Akt and ERK1/2 in BMSCs from acute leukemia patients. These findings suggest that Rg3 interferes with the activation of Akt and MAPK pathways in BMSCs, thereby regulating HIF-1α and VEGF expression by inhibiting the activity of Akt and ERK kinases. This underscores the role of Rg3 in targeting critical signaling pathways to modulate the tumor microenvironment and inhibit leukemia progression. The effects of Ginsenoside Rg3 on cancer progression, angiogenesis, oxidative stress, and its involvement in key molecular pathways are summarized in Table 2.

Ginsenoside Rg3 plays a pivotal role in the regulation of cellular metabolism by modulating the key pathways involved in energy production and nutrient utilization. It inhibits glycolysis in cancer cells, thereby reducing their energy supply and enhancing mitochondrial function to improve the cellular energy balance [78]. Rg3 activates AMP-activated protein kinase (AMPK), which promotes fatty acid oxidation, glucose uptake, and mitochondrial biogenesis while concurrently inhibiting anabolic processes [79]. In addition, it improves insulin sensitivity, regulates fatty acid metabolism, and modulates protein metabolism, thereby contributing to enhanced metabolic health. These results suggest that Rg3 is a promising therapeutic agent for various diseases, including cancer and metabolic disorders.

Ginsenoside Rg3 has demonstrated potential in modulating cellular energy metabolism, particularly within cancer cells, by influencing key metabolic pathways, such as glycolysis and mitochondrial function. This is particularly pertinent in the context of the Warburg effect, a phenomenon wherein cancer cells predominantly rely on aerobic glycolysis (the conversion of glucose to lactate) rather than oxidative phosphorylation for energy production, even in the presence of oxygen [80,81].

Inhibition of Glycolysis: The Warburg effect is a hallmark metabolic shift observed in numerous cancer cells, characterized by a preference for glycolysis over oxidative phosphorylation, even in the presence of oxygen. This metabolic reprogramming results in the upregulation of key glycolytic enzymes including lactate dehydrogenase A, hexokinase 2 (HK2), and pyruvate kinase M2 (PKM2) [82]. These enzymes facilitate the accelerated conversion of glucose to lactate, thereby providing cancer cells with the requisite energy and biosynthetic intermediates to support rapid growth and proliferation. Rg3 inhibits key glycolytic enzymes, thereby suppressing the glycolytic pathway. This inhibition leads to a reduction in lactate production, depriving cancer cells of a crucial source of energy and metabolic intermediates, rendering them less capable of sustaining rapid proliferation and survival.

Zhou et al. demonstrated the inhibition of glycolysis in SKOV3 ovarian cancer cell lines through the application of 20(S)-Rg3, which downregulated the expression of key glycolytic enzymes such as HK2 and PKM2 [83]. Their study further revealed that 20(S)-Rg3 modulated HK2 expression via the DNMT3A/miR-532-3p signaling axis. This pathway alteration contributed to the suppression of the Warburg effect in ovarian cancer cells. Moreover, in vivo experiments using nude mouse xenograft models confirmed that 20(S)-Rg3 treatment reduced HK2 expression, supporting its potential as a metabolic regulator in ovarian cancer therapy.

Mitochondrial Function and Oxidative Phosphorylation: Rg3 also influences mitochondrial function. Cancer cells frequently exhibit compromised mitochondrial function due to a metabolic shift towards glycolysis. Rg3 has been reported to enhance mitochondrial function by promoting mitochondrial biogenesis, augmenting oxidative phosphorylation, and increasing ATP production via mitochondria [84]. This transition towards oxidative metabolism can help restore the normal balance of cellular energy production, thereby limiting the survival advantage conferred by glycolytic metabolism in cancer cells.

Treatment with Rg3 in mouse-derived myoblast cell line (C2C12) activated key proteins in the insulin signaling pathway, such as insulin receptor substrate-1 (IRS-1) and Akt [85]. Rg3 was found to elevate ATP production and increase the oxygen consumption rate, indicating enhanced mitochondrial function. Additionally, Rg3 upregulated the expression of key transcription factors involved in mitochondrial biogenesis, including peroxisome proliferator-activated receptor γ coactivator 1α, nuclear respiratory factor 1 (NRF-1), and mitochondrial transcription factor A. These findings suggest that Rg3 promotes mitochondrial function and biogenesis, which may contribute to improved cellular energy metabolism and potentially enhance therapeutic response in cancer cells. This led to a subsequent increase in the expression of mitochondrial complex IV and V.

Regulation of Key Metabolic Pathways: Rg3 also influences critical metabolic regulators, such as AMPK and the mTOR pathway, which are essential for cellular energy sensing and metabolic reprogramming in cancer cells [86]. By activating AMPK, Rg3 can inhibit the mTOR signaling pathway, which is frequently overexpressed in cancer and promotes anabolic processes including protein and lipid synthesis [87]. This inhibition reduces cancer cell metabolism and growth, further limiting their ability to thrive under the altered metabolic conditions that are characteristic of the Warburg effect.

Treatment with ginsenoside Rg3 in transverse aortic constriction (TAC)-induced mouse models enhanced heart function while preserving both the mitochondrial structure and function (Fig. 6) [88]. An integrated analysis of metabolomics, proteomics, and targeted metabolomics data revealed that Rg3 regulates glycolysis, influences glucose uptake, and alleviates myocardial insulin resistance. The molecular mechanism underlying Rg3’s regulation of glucose metabolism was further investigated by examining the interaction pathways involving AMPK, insulin resistance, and glucose metabolism. Rg3 promoted glucose absorption in insulin-resistant H9c2 cells, a rat cardiomyoblast cell line, through the stimulation of AMPK, and this effect relied on the insulin signaling pathway, highlighting Rg3’s potential as a therapeutic agent for promoting myocardial glucose metabolism under conditions of insulin resistance.

Overall Impact on Cancer Metabolism: Rg3 disrupts the metabolic flexibility that cancer cells depend on for rapid growth by simultaneously targeting both the glycolytic pathway and mitochondrial function. This essentially compels cancer cells to revert to more normal metabolic processes, thereby reducing their efficiency in producing the energy required for continued survival and proliferation. This dual action on glycolysis and mitochondrial function represents a promising strategy for targeting cancer metabolism and is increasingly being recognized as an effective therapeutic approach in cancer treatment.

Ginsenoside Rg3 has been extensively reported to mitigate oxidative stress, a central factor in both skin aging and tumor progression, by orchestrating multiple antioxidant mechanisms. Oxidative stress arises from an imbalance between ROS generation and the cellular antioxidant defense system, leading to damage of lipids, proteins, and DNA. Rg3 contributes to redox homeostasis by directly scavenging ROS and downregulating their intracellular accumulation, thus protecting skin cells from photoaging and inflammation while simultaneously inhibiting ROS-driven proliferation in cancer cells. Mechanistically, Rg3 enhances the activity and expression of key antioxidant enzymes, including catalase, superoxide dismutase (SOD), and glutathione peroxidase (GPx), which together neutralize harmful oxidants and preserve cellular integrity. For instance, studies have demonstrated that Rg3 treatment significantly elevated these enzyme levels in cyclophosphamide-induced oxidative injury models, while reducing markers of oxidative damage such as malondialdehyde and nitric oxide [89]. In addition to enzyme activation, Rg3 activates the Nrf2/Keap1 signaling pathway, a master regulatory axis of antioxidant response. Upon activation, Nrf2 translocates into the nucleus and upregulates a battery of cytoprotective genes, including heme oxygenase-1 (HO-1), NAD(P)H quinone dehydrogenase 1 (NQO1), and glutathione peroxidase 4 (GPX4), reinforcing the cellular defense system. Notably, Rg3-mediated Nrf2 activation has also been linked to the suppression of ferroptosis and ischemia-induced tissue injury, illustrating its potential beyond classical ROS neutralization. Furthermore, the modulation of oxidative stress by Rg3 has downstream effects on inflammatory and apoptotic signaling pathways, such as NF-κB and caspase cascades, thereby integrating redox regulation with immune modulation and cell survival. These antioxidant properties position Rg3 as a promising therapeutic agent that not only preserves skin health but also counteracts the oxidative microenvironment that supports tumor growth and metastasis.

Reduction of ROS: Rg3 aids in reducing oxidative stress by directly scavenging ROS and lowering intracellular levels [90]. ROS are highly reactive molecules that are capable of damaging lipids, proteins, and DNA, leading to cell dysfunction and death. In skin cells, this can result in accelerated aging, inflammation, and pigmentation, whereas in cancer cells, ROS accumulation can promote tumor growth and metastasis. By neutralizing ROS, Rg3 protects the cells from oxidative damage and mitigates its deleterious effects. For instance, Sun et al. reported that ROS production increased in Lewis lung carcinoma (LLC) cells grown in serum-containing media compared with LLC cells cultured in serum-free media [91]. Elevated ROS levels were found to induce the proliferation of LLC cells. However, treatment with Rg3 (200 ng/mL) reduced ROS levels, leading to significant inhibition of cell proliferation. Rg3 treatment also notably decreased the expression of cyclins and cyclin-dependent kinases, which are crucial for cell cycle progression in LLC cells. Additionally, Rg3 suppressed the activation of MAPKs and induced apoptosis in LLC cells by activating pro-apoptotic proteins and suppressing anti-apoptotic proteins. These results suggest that Rg3 inhibits tumor cell proliferation and promotes apoptosis by modulating key molecular pathways.

Upregulation of antioxidant enzymes Rg3 enhances the cellular antioxidant defense system by upregulating the expression and activity of key antioxidant enzymes such as catalase, SOD, and GPx [92]. These enzymes play a pivotal role in neutralizing ROS and maintaining cellular redox balance. SOD converts superoxide radicals into hydrogen peroxide (H₂O₂), which is subsequently decomposed into water by catalase and GPx, thereby detoxifying harmful ROS and preventing cellular damage. By boosting the activity of these enzymes, Rg3 strengthens the cell’s natural antioxidant defenses and reduces the burden of oxidative stress. Wei et al. demonstrated that Rg3 inhibited cyclophosphamide (Cy)-induced oxidative stress in mice by increasing the indices of the spleen and thymus as well as enhancing the overall antioxidant capacity [89]. Rg3 treatment elevated the activities of key antioxidant enzymes, including catalase, superoxide dismutase, and lysozyme, while simultaneously decreasing xanthine oxidase activity. Additionally, Rg3 reduced the levels of malondialdehyde and nitric oxide, which are markers of oxidative damage. These findings suggest that Rg3 possesses potent antioxidant properties, providing defense against oxidative stress induced by cyclophosphamide.

Activation of the Nrf2 Signaling Pathway: The Nrf2 pathway serves as a pivotal regulator of antioxidant responses [93]. Rg3 activates the Nrf2 pathway, resulting in elevated expression of various antioxidant and cytoprotective genes [94]. The activation of Nrf2 enhances cellular resilience against oxidative stress by upregulating genes involved in detoxification, ROS scavenging, and glutathione synthesis. This extensive antioxidant response provides comprehensive defense against oxidative damage, thereby benefiting both skin health and cancer prevention. Zhong et al. reported that Rg3 upregulated the expression of the ferroptosis-related protein GPX4 and reduced iron accumulation in mice with myocardial ischemia/reperfusion (MI/R) injury (Fig. 7) [95]. Furthermore, Rg3 activates the Nrf2 signaling pathway, which plays a crucial role in mitigating myocardial ischemia-induced ferroptosis. Notably, Rg3 modulated the keap1/Nrf2 signaling pathway to alleviate oxygen-glucose deprivation/reperfusion (OGD/R)-induced ferroptosis in H9C2 cells. These findings suggest that Rg3 mitigates myocardial ischemia-induced ferroptosis through the keap1/Nrf2/GPX4 signaling pathway, underscoring its potential as a protective agent against oxidative and iron-induced cellular damage.

Protective Effects in Skin Care and Cancer: In the realm of skin care, the antioxidant properties of Rg3 are instrumental in combating photoaging, reducing inflammation, and protecting against UV-induced skin damage. Thus, Rg3 is a valuable ingredient in formulations aimed at mitigating the signs of aging and promoting healthy, resilient skin. In the context of cancer prevention and therapy, Rg3’s ability to reduce oxidative stress can limit damage to normal cells, protect cellular DNA from mutations, and suppress pathways that drive tumorigenesis. Furthermore, in cancer cells that thrive under oxidative conditions, Rg3’s antioxidant activity may diminish their survival advantage.

By decreasing oxidative stress and enhancing antioxidant defenses, Rg3 contributes to both skin protection and cancer suppression, underscoring its potential as a therapeutic agent for preventing oxidative damage across various biological systems.

Ginsenoside Rg3 exhibits potential synergistic effects when combined with other therapeutic agents, thereby enhancing its application in both skincare and anticancer treatments. Synergy in this context refers to the phenomenon in which the combined use of Rg3 with other compounds or treatments results in a greater overall effect than when each is used individually [96]. This property renders Rg3 particularly promising for augmenting the efficacy of various treatments, including traditional cancer therapies and advanced skin care formulations.

Enhanced Chemotherapy and Radiotherapy Efficacy: Rg3 has been shown to improve the effectiveness of chemotherapeutic agents such as paclitaxel, cisplatin, and doxorubicin in eradicating cancer cells [97]. This is achieved by sensitizing cancer cells to these drugs, potentially allowing for lower dosages, which can mitigate the side effects associated with high-dose chemotherapy. For instance, Jiang et al. reported that Ginsenoside Rg3 attenuates cisplatin resistance in lung cancer through the downregulation of PD-L1 [98]. Additionally, Rg3 can inhibit multidrug resistance (MDR) proteins, such as P-glycoprotein, which cancer cells often overexpress to expel chemotherapeutic drugs. This inhibition increases drug accumulation within the cells, thereby enhancing their sensitivity to treatment. Furthermore, Rg3 has been found to mitigate oxidative damage in normal cells caused by chemotherapy and radiotherapy, thus protecting healthy tissues while potentiating the anticancer effects of these treatments [99].

Combination with Other Natural Compounds in Skin Care: In skincare, Rg3 can act synergistically with other natural antioxidants, such as vitamin C, vitamin E, and green tea polyphenols, to enhance skin resilience against environmental stressors [100]. These combinations bolster skin defense mechanisms, reducing oxidative damage from UV exposure, pollution, and other environmental stressors. Rg3’s antioxidant effects complement those of other compounds by providing a broader range of ROS scavenging and anti-inflammatory benefits, which are particularly beneficial in formulations designed to protect and rejuvenate aging skin.

Inhibition of Tumor Progression with Immune Checkpoint Inhibitors and Targeted Therapies: Rg3 may synergize with immune checkpoint inhibitors (ICIs) and targeted therapies in cancer treatment [101]. For instance, Ginsenoside Rg3, in conjunction with a stimulator of interferon genes (STING) agonist, inhibited the proliferation of triple-negative breast cancer (TNBC) cells, reduced TNBC cell stemness and the EMT process, and promoted apoptosis in TNBC cells (Fig. 8) [102]. Additionally, the combination of Rg3 and a STING agonist modified the tumor microenvironment by inducing tumor-associated macrophage (TAM) M1 polarization and reversing TAM M2 polarization. Studies have suggested that Rg3 can modulate immune responses, potentially enhancing the antitumor effects of ICIs by reducing inflammation and improving immune surveillance. Similarly, Rg3’s inhibition of angiogenesis and metastasis complements targeted therapies that focus on specific tumor growth pathways, potentially leading to improved outcomes in tumor control and regression.

Enhanced Bioavailability and Efficacy of Co-Administered Agents: Rg3 is frequently incorporated into nanoformulations or co-administered with other agents to enhance its bioavailability and stability [103]. When utilized in conjunction with nanoparticle systems or encapsulated alongside other therapeutic agents, Rg3 facilitates improved cellular uptake and more effective delivery to target tissues, particularly tumors. These systems also offer protection against Rg3 degradation, thereby extending its activity and augmenting its therapeutic effects in combination with other compounds. For example, Zhang et al. developed Rg3-PLGA@TMVs by encapsulating ginsenoside Rg3 within poly(lactic-co-glycolic acid) (PLGA) nanoparticles and subsequently coating them with tumor cell-derived microvesicle (TMV) membranes [104]. Rg3-PLGA@TMVs exhibited several key advantages, including controlled drug release, enhanced storage stability, high drug-loading efficiency, and capacity to effectively activate dendritic cells. This activation was characterized by an increase in CD86+CD80+ dendritic cells, a reduction in phagocytic activity, and lower acid phosphatase levels, indicating a shift towards a more mature and activated dendritic cell phenotype. When used in combination with doxorubicin (DOX), Rg3-PLGA@TMVs demonstrated a synergistic effect, significantly inhibiting 4T1 tumor growth, a murine mammary carcinoma cell line model of triple-negative breast cancer, and promoting antitumor immunity in tumor-bearing mice. Notably, Rg3-PLGA@TMVs also mitigated the deleterious effects of DOX on normal cells and organs, particularly cardiotoxicity, thereby providing a safer and more effective therapeutic option. Overall, the synergistic potential of Rg3 across therapeutic domains renders it a versatile candidate for enhancing drug therapies and skincare solutions. Whether combined with pharmaceuticals or natural bioactives, Rg3 can amplify desired outcomes, reduce side effects, and offer a more comprehensive approach to managing skin health and cancer treatment.

Ginsenoside Rg3 exerts therapeutic effects by targeting a range of molecular pathways that regulate cellular survival, proliferation, and apoptosis, rendering it effective for both skin care and cancer treatment. In cancer cells, Rg3 modulates critical signaling pathways implicated in cell cycle control, including PI3K/Akt and MAPK, which are frequently overexpressed in tumors and drive cancer cell growth and resistance to apoptosis [105]. By inhibiting these pathways, Rg3 inhibits cancer cell survival and proliferation. It also targets pro-apoptotic and anti-apoptotic proteins within the Bcl-2 family, thereby enhancing apoptosis by promoting caspase activation and mitochondrial dysfunction. The effect of Rg3 on angiogenesis involves the downregulation of VEGF and suppression of MMPs, thereby limiting the tumor’s ability to grow new blood vessels and invade the surrounding tissues. Additionally, in skincare, Rg3 activates antioxidant pathways, particularly the Nrf2 pathway, upregulating the expression of antioxidant enzymes that neutralize ROS and reduce oxidative stress. Collectively, these mechanisms make Rg3 a versatile agent with potential benefits across multiple molecular targets, enabling both anticancer and protective effects.

Despite promising preclinical results, significant gaps persist in research on Rg3, particularly regarding its application in clinical settings. One of the primary limitations is the paucity of large-scale, well-controlled clinical trials that evaluate the efficacy, safety, and optimal dosage of Rg3 in humans, for both skincare and anticancer applications. The pharmacokinetics and metabolism of Rg3 in humans remain poorly understood, particularly in terms of bioavailability, absorption, and elimination. Although Rg3 demonstrates strong bioactivity in vitro and in animal models, its bioavailability in humans is low owing to poor water solubility and rapid metabolism; therefore, innovative delivery systems or formulation improvements are necessary to enhance its bioavailability. Furthermore, the pathways of Rg3 metabolism in humans and their potential interactions with other drugs or bioactive compounds require further investigation to ensure safe and effective therapeutic use. Additionally, research on the long-term effects and potential toxicity of high doses of Rg3 is limited, particularly when used in combination with other therapies.

Future research on ginsenoside Rg3 should focus on several critical areas to fully realize its therapeutic potential. Clinical trials are essential to confirm Rg3’s efficacy and safety in human subjects, with particular emphasis on optimal dosing, side effects, and drug interactions, especially when combined with other treatments like chemotherapy and radiotherapy. These studies will be pivotal in establishing Rg3 as a safe and effective therapeutic option. Additionally, investigating Rg3’s molecular targets in human cancer and skin cells will provide deeper insights into its mechanistic pathways, refining its therapeutic effects and guiding its application in personalized medicine. To maximize its clinical utility, developing advanced delivery systems such as nanoparticle carriers, liposomes, or other novel formulations is crucial to improve Rg3’s bioavailability and ensure targeted delivery. These systems will enhance its systemic absorption for anticancer therapy and percutaneous absorption for topical applications, making Rg3 more effective in various treatment contexts. Furthermore, exploring the synergy of Rg3 with other therapies—such as chemotherapy, immune checkpoint inhibitors, and targeted therapies—can lead to enhanced therapeutic outcomes, particularly in cancer treatment, by boosting efficacy and reducing side effects. Finally, regulatory and formulation studies are necessary to evaluate Rg3’s pharmacokinetics, pharmacodynamics, and stability across different formulations, ensuring its safe and effective use in clinical practice.

To address the current research gaps, future studies should focus on specific clinical investigations that confirm the therapeutic efficacy and safety of Rg3 in human subjects, with a focus on dose optimization and assessing potential drug-drug interactions and side effects. Research examining the mechanistic pathways of Rg3 in human cancer and skin cells would deepen our understanding of its therapeutic effects and refine its targeted applications. Improving the bioavailability of Rg3 is also a crucial direction, which could be achieved through the development of advanced formulations such as nanoparticle carriers, liposomes, or other novel delivery systems designed to enhance percutaneous absorption for topical applications or systemic delivery for anticancer therapy. Additionally, research could explore the role of Rg3 as a combination agent in both skincare and oncology by examining how it interacts with other active compounds or treatments to maximize therapeutic efficacy while minimizing side effects. These directions would bring Rg3 closer to being a reliable therapeutic option with clinically proven efficacy for human applications.

Furthermore, exploring the synergistic effects of Rg3 with other therapeutic agents could open new avenues for combination treatments, particularly in oncology. Finally, advancements in biotechnology could enable the production of Rg3 in larger quantities, making it more accessible for research and clinical applications. Overall, while significant progress has been made, continued research into ginsenoside Rg3 promises to unlock new therapeutic potentials and improve health outcomes.

In conclusion, ginsenoside Rg3 exhibits substantial therapeutic potential across a broad spectrum of medical applications, particularly in anticancer, anti-inflammatory, neuroprotective, and cardiovascular health domains. The distinct biological activities of its isomeric forms, 20(S)-Rg3 and 20(R)-Rg3, provide valuable insights into their multifaceted mechanisms of action, including the regulation of apoptosis, inflammation, and oxidative stress. Despite its potential, challenges such as the persistence of bioavailability can be addressed through innovative strategies such as nanoencapsulation and prodrug development. Furthermore, Rg3’s ability to synergize with other therapeutic agents suggests its role in bridging conventional and emerging treatment modalities in both oncology and dermatology. To fully realize its clinical potential, future research should prioritize refining delivery methods, understanding its precise molecular targets, and conducting rigorous clinical trials to validate its efficacy in diverse therapeutic settings.